Subtype
Malignant Urinary System Neoplasm
CI-CAN-00001187Explore in graph →
888 active trials28 approved drugs109 evidence items
- NCIt
- C9297
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001187Explore in graph →
Clinical trials
3,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (556)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00913913 | Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients | terminated | Phase 2 | 8 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Dec 1, 2015 | clinicaltrials |
| NCT00585689 | Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer | completed | Phase 2 | 29 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT00459875 | Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer | completed | Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 26, 2015 | clinicaltrials |
| NCT00024258 | Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors | completed | Phase 2 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2015 | clinicaltrials |
| NCT00714948 | Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma | terminated | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 16, 2015 | clinicaltrials |
| NCT00479089 | Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer | terminated | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT00704938 | Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer | terminated | Phase 2 | 3 | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00635726 | Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer | terminated | Phase 2 | 41 | Hellenic Oncology Research GroupOTHER | 1 | Oct 8, 2015 | clinicaltrials |
| NCT01342627 | Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma(SERCC) | terminated | Phase 2 | 4 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT01100242 | Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 17 | New Mexico Cancer Research AllianceOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT00995488 | Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer | terminated | Phase 2 | 16 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 11, 2015 | clinicaltrials |
| NCT02547350 | Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas | unknown | Phase 2 | 200 | Xuesong LiOTHER | 0 | Sep 11, 2015 | clinicaltrials |
| NCT01071928 | Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma | withdrawn | Phase 2 | 0 | Hoosier Cancer Research NetworkOTHER | 0 | Aug 19, 2015 | clinicaltrials |
| NCT01824329 | Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer(SPARC) | completed | Phase 2 | 40 | University of MichiganOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT02002312 | Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer | completed | Phase 2 | 14 | Radboud University Medical CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT00574483 | Treatment of Advanced Renal Cell Carcinoma With Quinacrine | withdrawn | Phase 2 | 0 | Cleveland BioLabsINDUSTRY | 1 | Aug 3, 2015 | clinicaltrials |
| NCT00556621 | Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer(GEMCIRAV) | completed | Phase 1 / Phase 2 | 14 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jul 30, 2015 | clinicaltrials |
| NCT00421889 | A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | completed | Phase 1 / Phase 2 | 80 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT00047216 | Tipifarnib in Treating Patients With Recurrent Bladder Cancer | completed | Phase 2 | — | University Health Network, TorontoOTHER | 2 | Jul 23, 2015 | clinicaltrials |
| NCT00066352 | Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter | completed | Phase 2 | — | University Health Network, TorontoOTHER | 2 | Jul 23, 2015 | clinicaltrials |
| NCT00609934 | Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone | completed | Phase 1 / Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00420888 | ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 / Phase 3 | 526 | Active Biotech ABINDUSTRY | 5 | Jul 22, 2015 | clinicaltrials |
| NCT00126490 | Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2015 | clinicaltrials |
| NCT00854620 | Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer | completed | Phase 2 | 9 | Stanford UniversityOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT00176280 | Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | University of KentuckyOTHER | 0 | Jun 18, 2015 | clinicaltrials |
| NCT00601926 | Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer | terminated | Phase 2 | 5 | Paul MonkOTHER | 1 | Jun 15, 2015 | clinicaltrials |
| NCT01316874 | Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)(Bladder Cancer) | completed | Phase 2 / Phase 3 | 90 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 1 | Jun 12, 2015 | clinicaltrials |
| NCT00855452 | Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors(rIL-2(LAK)) | completed | Phase 2 | 20 | Hadassah Medical OrganizationOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT02030717 | Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma(ASA) | completed | Phase 2 / Phase 3 | 120 | Umeå UniversityOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT01374789 | PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer(PURO) | terminated | Phase 2 | 2 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 1 | Jun 3, 2015 | clinicaltrials |
| NCT00796757 | A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC). | completed | Phase 2 | 146 | Hoffmann-La RocheINDUSTRY | 12 | May 27, 2015 | clinicaltrials |
| NCT00083109 | Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer | completed | Phase 1 / Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | May 25, 2015 | clinicaltrials |
| NCT00731211 | Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 57 | SCRI Development Innovations, LLCOTHER | 1 | May 20, 2015 | clinicaltrials |
| NCT01600339 | A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC) | completed | Phase 2 | 19 | Rambam Health Care CampusOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT02278978 | BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma | unknown | Phase 2 | 129 | National Taiwan University HospitalOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT02007005 | Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 37 | Abnoba GmbhINDUSTRY | 2 | May 6, 2015 | clinicaltrials |
| NCT02422277 | Role of Low-intensity Shock Wave Therapy in Penile Rehabilitation Post Nerve Sparing Radical Cysto-prostatectomy | unknown | Phase 2 | 60 | Mansoura UniversityOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT00019955 | Radiofrequency Interstitial Tissue Ablation in Treating Patients With Localized Renal Cell Carcinoma (Kidney Cancer) | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00949455 | A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium(LaMB) | unknown | Phase 2 / Phase 3 | 204 | Queen Mary University of LondonOTHER | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00422019 | A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma | completed | Phase 2 | 61 | AmgenINDUSTRY | 0 | Apr 10, 2015 | clinicaltrials |
| NCT00933374 | Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma(RAD001) | terminated | Phase 2 | 28 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Mar 18, 2015 | clinicaltrials |
| NCT00050323 | Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 30 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT01720693 | Novel Controlled Hypo-Perfusion Technique in Partial Nephrectomy | terminated | Phase 2 | 3 | University Health Network, TorontoOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT02006667 | A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer | completed | Phase 2 | 13 | Hoffmann-La RocheINDUSTRY | 1 | Feb 11, 2015 | clinicaltrials |
| NCT01791387 | 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC(DILIGENCE-1) | unknown | Phase 2 | 30 | Auckland District Health BoardOTHER_GOV | 1 | Feb 3, 2015 | clinicaltrials |
| NCT02345499 | Open Versus Laparoscopic Radical Cystectomy(OvsL) | unknown | Phase 2 | 80 | Azienda Ospedaliero-Universitaria Consorziale Policlinico di BariOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00136175 | Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder | completed | Phase 2 | 68 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 21, 2015 | clinicaltrials |
| NCT00126503 | Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jan 15, 2015 | clinicaltrials |
| NCT00661375 | BAY43-9006 Phase II Study for Renal Cell Carcinoma | completed | Phase 2 | 131 | BayerINDUSTRY | 1 | Dec 25, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Dec 1, 2015source: clinicaltrials